Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PRISM: Determination of the Performance Characteristics of ReQuest (TradeMark) in Practice in the Stepped Down Management of GORD

NCT00261339 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT00261339
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00261339 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PRISM: Determination of the Performance Characteristics of ReQuest (TradeMark) in Practice in the Stepped Down Management of GORD
Lead sponsor
Takeda
Phase
Phase 4
Overall status
Completed
Start date
August 31, 2005
Completion date
Not reported
Enrollment
300
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

gastroesophageal reflux, gerd, gord